Resveratrol at 20 mg/kg daily reversed polycystic ovary syndrome markers in rats by blocking pyroptosis—an inflammatory form of programmed cell death—in ovarian granulosa cells. The intervention reduced testosterone levels, normalized estrous cycles, and downregulated key inflammatory markers including TNF-α, NLRP3, and IL-6, while simultaneously suppressing pyroptosis markers GSDMD and cleaved-Caspase-1. This mechanistic insight into resveratrol's anti-PCOS effects represents a significant advance beyond previous studies that focused primarily on metabolic improvements. The identification of pyroptosis as a therapeutic target opens new avenues for PCOS treatment, as this inflammatory cell death pathway contributes to the chronic ovarian dysfunction characteristic of the condition. The 15 μM concentration that proved effective in human granulosa-like cells provides a translatable benchmark for clinical applications. However, the rat dosage translates to roughly 200mg daily for a 70kg human—substantially lower than the 1000mg used in the cited human trial. This discrepancy, along with the relatively short 30-day intervention period, suggests longer-term human studies with optimized dosing are needed to validate these promising mechanistic findings for the estimated 10% of reproductive-age women affected by PCOS.